PCSK9 and metabolic syndrome: The Phase 3 Clinical Research of Developing PCSK9 Inhibitor as Cholesterol-lowering Therapy in Chinese Patients with Dyslipidemia-2 (CREDIT-2) study demonstrated that tafolecimab led to significant and persistent reductions in LDL-C levels and showed a favorable safety profile in Chinese patients with heterozygous familial hypercholesterolemia (HeFH) [46].